Colorectal cancer, as a common cancer, is still poorly understood in terms of the molecular mechanisms of its pathogenesis. Despite the fact that research on the pathogenesis of colorectal cancer is gradually deepening and providing enhanced screening strategies, the prevalence of the disease is still on the rise due to the fact that early symptoms of the disease are not obvious and are difficult to diagnose, causing many patients to miss the best opportunity for surgical treatment. Most studies have shown that the early onset of colorectal cancer is mainly due to the role of the body's environment, diet, genetics and other factors present in the patient. Therefore, this article reviews the pathogenesis and main treatment methods of colorectal cancer in Chinese and Western medicine, aiming to provide a reference basis for the clinical prevention and treatment of this type of disease and the elucidation of the related pathologic mechanisms.

Yang Gang, Yang Hao, Wu Xiaoyu. Research Progress on the Pathogenesis of Colorectal Cancer and Integrated Traditional Chinese and Western Medicine Treatment. Academic Journal of Medicine & Health Sciences (2023) Vol. 4, Issue 11: 89-96. https://doi.org/10.25236/AJMHS.2023.041113.

[1] Malki Ahmed, ElRuz Rasha Abu, Gupta Ishita, et al. Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements [J]. International Journal of Molecular Sciences, 2021, 22(1):130.

[2] Codrich Marta, Dalla Emiliano, Mio Catia, et al. Integrated multi-omics analyses on patient-derived CRC organoids highlight altered molecular pathways in colorectal cancer progression involving PTEN [J]. Journal of Experimental & Clinical Cancer Research, 2021, 40(1):198-198. 

[3] Shaukat Aasma, Kahi Charles J, Burke Carol A, et al. ACG Clinical Guidelines: Colorectal Cancer Screening 2021 [J]. American Journal of Gastroenterology, 2021, 116(3):458-479. 

[4] National Health Commission of the People’s Republic of China, Chinese Society of Oncology, Gu Jin, Wang Jianping, Wang Xishan, et al. Chinese Protocol of Diagnosis and Treatment of Colorectal Cancer(2023 edition) [J]. Chinese Journal of Surgery, 2023, 61(8): 617-644. 

[5] Kannan Thanikachalam, Gazala Khan. Colorectal Cancer and Nutrition [J]. Nutrients, 2019, 11(1):164. 

[6] Mauri Gianluca, Sartore-Bianchi Andrea, Russo Antonio-Giampiero, et al. Early-onset colorectal cancer in young individuals [J]. Molecular oncology, 2019, 13(2):109-131. 

[7] Chen Eric Xueyu, Jonker Derek J., Kennecke Hagen F., et al. CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC) [J]. Journal of Clinical Oncology, 2019, 37(4):481-481.

[8] Deitrick J, Pruitt W M. Wnt/β Catenin-Mediated Signaling Commonly Altered in Colorectal Cancer [J]. Progress in molecular biology and translational science, 2016, 144:49-68. 

[9] Cheng Xiaofei, et al. Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer [J]. Biomedicine & Pharmacotherapy, 2019, 110:473-481. 

[10] Ammad Ahmad Farooqi, Marc de la Roche, Mustafa B A. Djamgoz, et al. Overview of the oncogenic signaling pathways in colorectal cancer: Mechanistic insights [J]. Seminars in Cancer Biology, 2019, 58:65-79. 

[11] Jiang Shuai, Li Qiwen, Liu Yimin, et al. Activation of WNT7b autocrine eases metastasis of colorectal cancer via epithelial to mesenchymal transition and predicts poor prognosis [J]. BMC Cancer, 2021, 21(1):180-180. 

[12] Lopez Anthony, Harada Kazuto, Vasilakopoulou Maria, et al. Targeting Angiogenesis in Colorectal Carcinoma [J]. Drugs, 2019, 79(1):63-74. 

[13] Li Rui, Yuan Yu, Cai Ting. Research Progress in the Pathogenesis of Colorectal Cancer and Treatment with Traditional Chinese and Western Medicine [J]. Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology, 2022, 24(1):289-297. 

[14] Ting Fu, Sally Coulter, Eiji Yoshihara, et al. FXR Regulates Intestinal Cancer Stem Cell Proliferation [J]. Cell, 2019, 176(5):1098-1112.e18. 

[15] Yin Yiming, Wang Mengge, Gu Wenjie, et al. Intestine-specific FXR agonists as potential therapeutic agents for colorectal cancer [J]. Biochemical Pharmacology, 2021, 186:114430-114430. 

[16] Hotta Masahiro, et al. Farnesoid X receptor induces cell death and sensitizes to TRAIL-induced inhibition of growth in colorectal cancer cells through the up-regulation of death receptor 5 [J]. Biochemical and biophysical research communications, 2019, 519(4):824-831. 

[17] Atena Soleimani, Farzad Rahmani, Gordon A. Ferns, et al. Role of the NF-κB signaling pathway in the pathogenesis of colorectal cancer [J]. Gene, 2020, 726:144132. 

[18] Meera Patel, Paul G. Horgan, Donald C. McMillan, et al. NF-κB pathways in the development and progression of colorectal cancer [J]. Translational Research, 2018, 197:43-56. 

[19] Jing Linlin, Sun Xuegang. Anti-cancer strategy based on pathogenesis of tumor microenvironment [J]. China Journal of Traditional Chinese Medicine and Pharmacy, 2017, 32(11):5001-5004. 

[20] Zhang Ying, Wang Fei, Zhao Zhangyang. Impact of the scientific mechanism of complexity of the spleen system of traditional Chinese medicine on the cancer recovery model [J]. Chinese Journal of Clinical Research, 2015, 28(12):1660-1661. 

[21] Zong Fangfang, Tan Jun, Shao Lei, et al. Intestinal flora enhance tumor therapeutic effect by modulating immune responses [J]. Industrial Microbiology, 2016, 46(1):53-56. 

[22] Zhang Ping, Li Fanghong, Ye Fajun. Observation on the clinical efficacy and improvement of quality of life of rectal cancer treated with anus-sparing surgery for low rectal cancer [J]. China Modern Doctor, 2020, 58(5):69-71. 

[23] Tan Tianying, Li Shuangshuang, Chen Xiaochao. Progression on the treatment of colorectal cancer with TCM, and Western medicine [J]. Chinese Journal of Coloproctology, 2022, 42(3):67-69. 

[24] He Sijia, Huang Qian, Li Qi. Progress on chemotherapy and targeted therapy in metastatic colorectal cancer [J]. World Clinical Drugs, 2020, 41(11):844-849. 

[25] Hou Xiaoru. Analysis of neoadjuvant radiotherapy alone and neoadjuvant concurrent radiotherapy and chemotherapy for locally advanced rectal cancer [J]. China Practical Medicine, 2012, 7(21):121-122. 

[26] Ding Chengsheng, Jin Zhiming. Progress in the study of immune checkpoint inhibitors for colon cancer [J]. Journal of Medical Research, 2021, 50(1):8-13. 

[27] Zeng Jiaxing, Ding Jie, Xia Yu, et al. Research progress of immunotherapy for colorectal cancer [J]. Chinese Journal of Oncology Prevention Aand Treatment, 2020, 12(6):691-695. 

[28] Zhao Jing, Hu Hanguang, Weng Shanshan, et al. Progress of immune checkpoint inhibitors in colorectal cancer [J]. Journal of Practical Oncology, 2020, 35(6):485-490. 

[29] Sun Bo, Wang Zhimin, Shen Jing, et al. Clinical Observation of Spleen-Nourishing and Qi-Boosting Method Plus Chemotherapy in Treating Advanced Colorectal Cancer [J]. Liaoning Journal of Traditional Chinese Medicine, 2015, 42(3): 518-521. 

[30] Li Yanxi, Qin Xiaoxue, Li Penglei, et al. Isobavachalcone isolated from Psoralea corylifolia inhibits cell proliferation and induces apoptosis via inhibiting the AKT/GSK-3β/β-catenin pathway in colorectal cancer cells [J]. Drug design, development and therapy, 2019, 13:1449-1460. 

[31] Park Gwang Hun, Song Hun Min, Park Su Bin, et al. Cytotoxic activity of the twigs of Cinnamomum cassia through the suppression of cell proliferation and the induction of apoptosis in human colorectal cancer cells [J]. BMC complementary and alternative medicine, 2018, 18(1):28. 

[32] Wang Shuren, Ma Kai, Zhou Cuiqi, et al. LKB1 and YAP phosphorylation play important roles in Celastrol-induced β-catenin degradation in colorectal cancer [J]. Therapeutic Advances in Medical Oncology, 2019, 11:1758835919843736. 

[33] Zhong Yu, Zheng Xuebao, Cai Kangrong, et al. Study of isobutyrylshikonin inhibiting proliferation of colon carcinoma cells through PI3K/Akt/m-TOR pathway [J]. China Journal of Chinese Materia Medica, 2018, 43(11):2358-2364. 

[34] Buhrmann Constanze, Shayan Parviz, Brockmueller Aranka, et al. Resveratrol Suppresses Cross-Talk between Colorectal Cancer Cells and Stromal Cells in Multicellular Tumor Microenvironment: A Bridge between In Vitro and In Vivo Tumor Microenvironment Study [J]. Molecules, 2020, 25(18):4292-4292. 

[35] Koi Minoru, Carethers John M. The colorectal cancer immune microenvironment and approach to immunotherapies [J]. Future oncology (London, England), 2017, 13(18):1633-1647. 

[36] Hu Bin, Li Gang, An Hongmei, et al. Effects of Tenglongbuzhong decoction on Th1 immune response in patients with advanced colorectal cancer[J]. Chinese Journal of Integrated Traditional and Western Medicine on Digestion, 2014, 22:434-436+439. 

[37] Niu Guoping, Sun Li, Pei Yunfeng, et al. Oleanolic Acid Inhibits Colorectal Cancer Angiogenesis by Blocking the VEGFR2 Signaling Pathway [J]. Anti-cancer agents in medicinal chemistry, 2018, 18(4):583-590. 

[38] Lin Wei, Zheng Liangpu, Zhuang Qunchuan, et al. Spica prunellae promotes cancer cell apoptosis, inhibits cell proliferation and tumor angiogenesis in a mouse model of colorectal cancer via suppression of stat3 pathway [J]. BMC complementary and alternative medicine, 2013, 13(1):144. 

[39] Cheng Lingge, Liu Wenyue, Zhong Chongjin, et al. Remodeling the homeostasis of pro- and anti-angiogenic factors by Shenmai injection to normalize tumor vasculature for enhanced cancer chemotherapy [J]. Journal of Ethnopharmacology, 2020, 270:113770. 

[40] Tang Yuchen, et al. Ginsenoside Rg3 targets cancer stem cells and tumor angiogenesis to inhibit colorectal cancer progression in vivo [J]. International journal of oncology, 2018, 52(1):127-138.